A definitive diagnosis of Alzheimer’s disease (AD) was once only possible after someone had died, but recent biomarker studies have led to the development of imaging and spinal fluid tests for those still living. However, the tests can only monitor severe disease, differentiating advanced AD from related disorders. Reporting on November 9, 2022 in ACS Chemical Neuroscience, researchers have now identified a biomarker that could help physicians diagnose AD earlier, as a patient transitions into mild cognitive impairment (MCI). The article is titled “Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation.”
Login Or Register To Read Full Story